Evidence map›Paper›PMID 30151266›Full record

ArticleJournal of gastrointestinal oncology2018

Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma.

Victor Hugo Fonseca de Jesus, Marcos Pedro Guedes Camandaroba, Mauro Daniel Spina Donadio, Audrey Cabral, Thiago Pimentel Muniz, Luciana de Moura Leite, Lucas Ferreira Sant'Ana

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Victor Hugo Fonseca de JesusDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Marcos Pedro Guedes CamandarobaDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Mauro Daniel Spina DonadioDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Audrey CabralDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Thiago Pimentel MunizDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Luciana de Moura LeiteDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Lucas Ferreira Sant'AnaDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
AC Camargo Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFOLFIRINOX stands a major breakthrough in the management of metastatic pancreatic adenocarcinoma (MPA). Nonetheless, significant side-effects have been reported using standard FOLFIRINOX. We aimed to compare survival outcomes, response rates and toxicity of patients treated with standard or modified FOLFIRINOX in MPA.

methodsWe included patients aged ≥18 years old, with pathologically confirmed MPA, treated with FOLFIRINOX in the first-line setting. Patients submitted to at least one cycle of full-dose FOLFIRINOX were grouped in the standard FOLFIRINOX group.

resultsPatients treated with standard FOLFIRINOX were younger and had less comorbidity. We observed no differences in overall survival or in progression-free survival between the two treatment arms. The only variable independently associated with OS was log10[neutrophil-to-lymphocyte ratio (NLR)]. Modified FOLFIRINOX was associated with a lower dose reduction rate, but a slightly increased incidence of severe toxicity.

conclusionsModified FOLFIRINOX presents the same activity against MPA as standard FOLFIRINOX. We found no significant differences in toxicity, possibly due to patient selection and a higher dose reduction rate in the standard FOLFIRINOX arm. NLR stood as an important prognostic marker and further research is needed to comprehend its biological meaning in pancreatic cancer.

Indexed as

carcinomaMetastasispancreastherapeutics

Identifiers

PMID30151266
PMCPMC6087866
OpenAlexW2801295380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.